The Hong Kong-listed biomedical industry was active in repurchases during the year, with 4 companies repurchasing more than 30 times

【Pharmaceutical Network Pharmaceutical Stock Market】 Share repurchase refers to the company's repurchase
of the company's shares issued or in circulation according to certain procedures.

According to iFinD data, as of September 26, 22 companies in the Hong Kong biomedical industry announced 381 repurchases during the year, involving a total amount of HK$3.
41 billion, compared with the same period of the previous year, both the number of repurchases and the amount involved have increased, which shows that the Hong Kong biomedical industry will be active
in repurchases in 2022.

From the single amount, the outstanding performance is the CRO head enterprise WuXi Biologics, which repurchased a total of HK$
843 million this year.

On September 26, WuXi Biologics once again planned to buy back its shares for no more than $300 million, while also mentioning that the company's financial position remains stable
.

According to the 2021 annual report, the company achieved revenue of 10.
29 billion yuan, an increase of 83.
3% year-on-year (compared with the same period last year); Net profit attributable to shareholders of listed companies was RMB3.
389 billion, an increase of 100.
6%
year-on-year.

The industry believes that China's CRO companies have the advantages of lower labor costs, shorter biologics production capacity construction cycle and economies of scale, and benefit from the engineer dividend, and there is still high growth in the future, according to the agency's expectations, by 2025, the domestic market size will exceed 150 billion yuan
.

Recently, Haitong International told WuXi Bioreview that it expects the company's revenue and profit to maintain rapid growth
in 22-23 years.

From the perspective of the number of individual stock buybacks, there are 4 companies that have repurchased more than 30 times, namely Yisheng Biotechnology, Meirui Health International, Fangda Holdings and Kangchen Pharmaceutical
.

Among them, E&S Biotechnology repurchased as many as 77 times during the year, involving an amount of HK$
10,072,100.

It is a research and development company whose main business is the manufacture and sale of biopharmaceuticals for the treatment of surface trauma and eye damage, as well as bFGF drugs for new indications (such as recombinant bovine basic fibroblast growth factor, also known as FGF-2) and other eye drug projects
.

In 2021, under various unstable factors, E&T Biotechnology still achieved strong growth and performance
.

Consolidated turnover in 2021 was approximately HK$1,638 million, an increase of 67.
4%
year-on-year.

Attributable to the increase in turnover, the Company recorded a profit after tax of approximately HK$346 million, an increase of 58%
year-on-year.

Meirui Health International followed closely behind, with 49 buybacks involving an amount of HK$
36.
6157 million.

The company is an investment holding company that buys and sells health care products, chemical materials and building materials
.

In 2021, the company's operating income was HK$253 million, down 4.
57% year-on-year, and net profit attributable to the parent company was HK$60.
323 million, down 27.
70% year-on-year, with basic earnings per share of HK$
0.
01.

The number of buybacks of Fangda Holdings during the year was 31, involving an amount of HK$
57,055,400.

According to the data, this is a CRO company with operations covering the United States and China, mainly providing integrated, science-driven research, analysis and development services
.

In recent years, the company's revenue has grown rapidly, reaching $184 million by 2021, with a compound annual growth rate of 29.
8%.


In addition, the number of buybacks of Kangchen Pharmaceutical was 30 times, involving an amount of HK$
34.
9438 million.

Kangchen Pharmaceutical is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals including nephrotic drugs, contrast media and others
.

In 2021, the company's net profit increased by 18.
3% to 590 million yuan, and sales revenue was 2.
045 billion yuan, an increase of 16.
6% year-on-year, breaking the 2 billion mark
for the first time.

For the purpose of the repurchase, many companies said that the share repurchase highlights the company's confidence in the development of their own business prospects, high recognition of the company's value and judgment of fundamentals, which is conducive to enhancing investor confidence
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.